drugset
Drugs / Camrelizumab
last change 10 days ago re-read 9 days ago

Camrelizumab

also known as SHR-1210 · Carrelizumab · Camrelizumab for injection · Carilizumab · AiRuiKa · Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China) · Aikening · CAM

Monoclonal antibody targets PDCD1 via inhibition

Developed for
hepatocellular carcinoma · esophageal squamous cell carcinoma · non-small cell lung carcinoma · gastric cancer · triple-negative breast carcinoma · nasopharyngeal carcinoma · cervical cancer · colorectal cancer
+117 more · esophageal cancer · breast cancer · head and neck squamous cell carcinoma · cancer · malignant pancreatic neoplasm · melanoma · small cell lung carcinoma · biliary tract cancer · gastric adenocarcinoma · carcinoma of esophagus · Her2-receptor negative breast cancer · intrahepatic cholangiocarcinoma · rectal cancer · soft tissue sarcoma · cervical carcinoma · gastroesophageal junction adenocarcinoma · Hodgkins lymphoma · digestive system cancer · gastroesophageal adenocarcinoma · gastroesophageal cancer · oral cavity squamous cell carcinoma · sarcoma · cholangiocarcinoma · classic Hodgkin lymphoma · extranodal nasal NK/T cell lymphoma · gastric neoplasm · gestational trophoblastic neoplasm · head and neck cancer · lung cancer · metastatic malignant neoplasm · neoplasm · osteosarcoma · acute myeloid leukemia · adrenal cortex carcinoma · colon carcinoma · endometrial cancer · female breast carcinoma · glioblastoma · HER2 positive breast carcinoma · hormone receptor-positive breast cancer · liver cancer · lung carcinoma · lung neoplasm · metastasis from malignant tumor of colon · metastatic malignant neoplasm in the brain · mucosal melanoma · pancreatic ductal adenocarcinoma · pancreatic exocrine neoplasm · acral lentiginous melanoma · adult glioblastoma · adult hepatocellular carcinoma · ALK-positive anaplastic large cell lymphoma · bone sarcoma · carcinoma of gallbladder and extrahepatic biliary tract · carcinosarcoma · cervical squamous cell carcinoma · chordoma · clear cell renal carcinoma · colorectal neoplasm · combined hepatocellular carcinoma and cholangiocarcinoma · dedifferentiated liposarcoma · differentiated thyroid carcinoma · diffuse large B-cell lymphoma · digestive system carcinoma · digestive system neoplasm · endometrial endometrioid adenocarcinoma · gallbladder cancer · gastric carcinoma · head and neck neoplasm · hematopoietic and lymphoid system neoplasm · hepatoblastoma · high grade astrocytic tumor · high grade B-cell lymphoma · high-grade neuroendocrine carcinoma of the cervix uteri · hypopharyngeal carcinoma · hypopharynx cancer · infiltrating bladder urothelial carcinoma · laryngeal neoplasm · lung adenocarcinoma · lung sarcomatoid carcinoma · lymphoma · metachronous osteosarcoma of the bone · metastatic carcinoma · metastatic neoplasm · nasal cavity cancer · nasopharyngeal neoplasm · neoplasm of esophagus · neoplastic disease or syndrome · neoplastic meningitis · neuroendocrine carcinoma · non-Hodgkin lymphoma · oral cavity cancer · oral cavity neoplasm · ovarian carcinoma · ovarian clear cell cancer · paranasal sinus cancer · pediatric osteosarcoma · peripheral T-cell lymphoma, not otherwise specified · pleural neoplasm · primary central nervous system lymphoma · primary mediastinal large B-cell lymphoma · primary organ-specific lymphoma · rectal carcinoma · renal cell carcinoma · salivary gland carcinoma · sarcomatoid carcinoma · skin squamous cell carcinoma · squamous cell carcinoma · squamous cell lung carcinoma · T-cell and NK-cell neoplasm · T-lymphoblastic lymphoma · thyroid cancer · transitional cell neoplasm · urinary bladder cancer · urinary bladder neoplasm · urothelial carcinoma · uterine cancer
Investigated by
Jiangsu HengRui Medicine Co., Ltd. · Sun Yat-sen University · Fudan University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Zhejiang Cancer Hospital · Peking Union Medical College Hospital
+211 more · Tianjin Medical University Cancer Institute and Hospital · Chinese PLA General Hospital · Henan Cancer Hospital · Jiangsu Hengrui Pharmaceutical Co., Ltd. · The First Affiliated Hospital of Zhengzhou University · Peking University Cancer Hospital & Institute · Hunan Cancer Hospital · Ruijin Hospital · West China Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Women's Hospital School Of Medicine Zhejiang University · Beijing Friendship Hospital · Qilu Hospital of Shandong University · Shanghai Zhongshan Hospital · Sichuan Cancer Hospital and Research Institute · The First Affiliated Hospital with Nanjing Medical University · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Chinese Academy of Medical Sciences · Harbin Medical University · Peking University People's Hospital · Chongqing University Cancer Hospital · Guangdong Provincial People's Hospital · Huazhong University of Science and Technology · Nanfang Hospital, Southern Medical University · Peking University · RenJi Hospital · Tongji Hospital · Anhui Provincial Cancer Hospital · Fujian Medical University · Hebei Medical University Fourth Hospital · Lei Li · Shandong Cancer Hospital and Institute · Shanghai Jiao Tong University School of Medicine · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai Pulmonary Hospital, Shanghai, China · Shengjing Hospital · Sichuan University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The First Affiliated Hospital of Xiamen University · Third Affiliated Hospital, Sun Yat-Sen University · Xiangya Hospital of Central South University · Zhejiang University · Cancer Hospital of Guangxi Medical University · China Medical University, China · First Affiliated Hospital Xi'an Jiaotong University · Fujian Cancer Hospital · Fujian Medical University Union Hospital · Jiangxi Provincial Cancer Hospital · Peking University Third Hospital · Shanghai Chest Hospital · Tianjin Medical University General Hospital · West China Second University Hospital · Wuzhou Red Cross Hospital · Yanqiao Zhang · Zhongshan Hospital Xiamen University · Zhongshan People's Hospital, Guangdong, China · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Beijing Sanbo Brain Hospital · Beijing Tsinghua Chang Gung Hospital · Di Wu · Eye & ENT Hospital of Fudan University · First Affiliated Hospital of Chongqing Medical University · First Affiliated Hospital of Wenzhou Medical University · First People's Hospital of Foshan · Fuzhou General Hospital · Gansu Provincial Maternal and Child Health Care Hospital · Guangxi Medical University · Guangzhou Virotech Pharmaceutical Co., Ltd. · Hangzhou Cancer Hospital · Hebei Medical University · Henan Provincial People's Hospital · Hospital of Stomatology, Wuhan University · Huashan Hospital · Hubei Cancer Hospital · all 217 on the full record

Trials 528 · started per year

today
1
6
15
30
50
102
112
73
44
42
29
24
2016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT06326736 Apr 2024 → Dec 2025 overdue malignant pancreatic neoplasm Jinling Hospital, China Recruiting No outcome recorded
Phase 0 NCT04074564 Nov 2019 → Aug 2024 sarcoma HRYZ Biotech Co. Unknown No outcome recorded
Phase 128 trials · 1 met primary
Phase 1 NCT06530082 Dec 2024 → Apr 2026 overdue breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting No outcome recorded
Phase 1 NCT06654297 Oct 2024 → Jun 2025 overdue esophageal squamous cell carcinoma West China Hospital Active not recruiting No outcome recorded
Phase 1 NCT06346808 May 2024 → May 2026 overdue malignant pancreatic neoplasm Sichuan University Not yet recruiting No outcome recorded
Phase 1 NCT06109207 Oct 2023 → Oct 2024 overdue head and neck squamous cell carcinoma West China Hospital Recruiting No outcome recorded
Phase 1 NCT05799183 Jul → Oct 2023 — Jiangsu HengRui Medicine Co., Ltd. Terminated No outcome recorded Stop: Business
Phase 1 NCT05643417 Dec 2022 → Oct 2023 liver cancer Fudan University Unknown No outcome recorded
Phase 1 NCT05198817 Feb 2022 → Jan 2023 cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. Unknown No outcome recorded
Phase 1 NCT05031949 Oct 2021 → Dec 2024 hepatocellular carcinoma Zhang Bi Xiang, MD Unknown No outcome recorded
Phase 1 NCT05008861 Sep 2021 → Dec 2022 non-small cell lung carcinoma Shanghai Zhongshan Hospital Unknown No outcome recorded
Phase 1 NCT05019534 Aug 2021 → Aug 2022 — West China Hospital Unknown No outcome recorded
Phase 1/250 trials · 1 met primary
Phase 1/2 NCT07662681 Jul 2026 → Jul 2028 expected head and neck cancer Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Recruiting No outcome recorded
Phase 1/2 NCT07641010 Jun 2026 → Sep 2028 expected Hodgkins lymphoma Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 1/2 NCT07190027 Nov 2025 overdue non-small cell lung carcinoma First Affiliated Hospital of Wenzhou Medical University Not yet recruiting No outcome recorded
Phase 1/2 NCT07161791 Sep 2025 → Dec 2026 expected triple-negative breast carcinoma Harbin Medical University Not yet recruiting No outcome recorded
Phase 1/2 NCT06376721 Apr 2024 → Oct 2026 expected T-lymphoblastic lymphoma, extranodal nasal NK/T cell lymphoma Beijing Tongren Hospital Recruiting No outcome recorded
Phase 1/2 NCT06124001 Nov 2023 → Dec 2025 hepatocellular carcinoma CNBG-Virogin Biotech (Shanghai) Ltd. Unknown No outcome recorded
Phase 1/2 NCT06055153 Sep 2023 → Feb 2025 esophageal squamous cell carcinoma Changhai Hospital Unknown No outcome recorded
Phase 1/2 NCT05937438 Sep 2023 → Sep 2025 overdue carcinoma of esophagus Anhui Provincial Hospital Recruiting No outcome recorded
Phase 1/2 NCT06010212 Aug 2023 → Aug 2025 esophageal squamous cell carcinoma The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
Phase 1/2 NCT05983237 Aug 2023 → Dec 2026 expected melanoma Jun Guo Recruiting No outcome recorded
Phase 2350 trials · 10 met primary · 1 missed
Phase 2 NCT06196671 Dec 2026 → Jan 2028 expected malignant pancreatic neoplasm Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07505186 Aug 2026 → Dec 2028 expected esophageal squamous cell carcinoma Second Affiliated Hospital, Zhejiang University, School of Medicine Recruiting No outcome recorded
Phase 2 NCT07627620 Jun 2026 → Sep 2027 expected cervical cancer Hunan Cancer Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07639983 Jun 2026 → Jun 2028 expected infiltrating bladder urothelial carcinoma Sheng Tai Not yet recruiting No outcome recorded
Phase 2 NCT07521605 May 2026 → Dec 2031 expected rectal cancer Guangdong Provincial People's Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07555860 Apr 2026 → Dec 2027 expected nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07528183 Apr 2026 → Apr 2032 expected nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07471815 Mar 2026 → Mar 2028 expected triple-negative breast carcinoma Harbin Medical University Active not recruiting No outcome recorded
Phase 2 NCT07314372 Feb 2026 → Dec 2027 expected adult hepatocellular carcinoma The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting No outcome recorded
Phase 2 NCT07395063 Feb 2026 → Feb 2029 expected colorectal cancer The Fourth Affiliated Hospital of Zhejiang University School of Medicine Not yet recruiting No outcome recorded
Show all 350 trials opens the full record — a long page
Phase 2/314 trials · 1 met primary
Phase 2/3 NCT07653451 Jul 2026 → Dec 2027 expected esophageal squamous cell carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2/3 NCT07589244 May 2026 → Dec 2028 expected hepatocellular carcinoma Guangzhou Virotech Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2/3 NCT06866951 Mar 2025 → Dec 2028 cervical cancer Women's Hospital School Of Medicine Zhejiang University Withdrawn No outcome recorded Stop: Enrollment
Phase 2/3 NCT06739317 Jan 2025 → Dec 2030 expected hepatocellular carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2/3 NCT06361888 May 2024 → May 2028 expected malignant pancreatic neoplasm Hutchmed Recruiting No outcome recorded
Phase 2/3 NCT06288373 Apr 2024 → Mar 2031 expected cervical cancer Tongji Hospital Recruiting No outcome recorded
Phase 2/3 NCT05322187 Apr 2022 → Sep 2023 childhood malignant neoplasm, hepatoblastoma, transitional cell neoplasm RenJi Hospital Unknown No outcome recorded
Phase 2/3 NCT04907344 Jun 2021 → Jun 2025 triple-negative breast carcinoma Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 2/3 NCT05062837 Jun 2021 → Dec 2026 expected hepatocellular carcinoma Guangxi Medical University Recruiting No outcome recorded
Phase 2/3 NCT04803539 Apr 2021 → Sep 2028 expected breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 347 trials · 10 met primary
Phase 3 NCT06889688 Feb 2025 → Dec 2028 expected triple-negative breast carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 3 NCT07016126 Dec 2024 → Dec 2027 expected non-small cell lung carcinoma Guangdong Provincial People's Hospital Recruiting No outcome recorded
Phase 3 NCT07016737 Aug 2024 → Sep 2027 expected esophageal squamous cell carcinoma Ye jinjun Enrolling by invitation No outcome recorded
Phase 3 NCT05738616 May 2024 → May 2027 expected hepatocellular carcinoma Wen Tianfu Recruiting No outcome recorded
Phase 3 NCT06339060 May 2024 → Mar 2028 expected esophageal squamous cell carcinoma Ruijin Hospital Recruiting No outcome recorded
Phase 3 NCT06313463 Mar 2024 → Sep 2031 expected breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 3 NCT05798793 Nov 2023 → Jul 2026 overdue oral cavity squamous cell carcinoma Hospital of Stomatology, Wuhan University Recruiting No outcome recorded
Phase 3 NCT06031597 Sep 2023 → Dec 2025 non-small cell lung carcinoma Zhejiang Cancer Hospital Unknown No outcome recorded
Phase 3 NCT06172205 Jul 2023 → Jul 2028 expected chemotherapy-induced toxicity, hepatocellular carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 3 NCT05862064 Jun 2023 → Jul 2026 overdue triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT06276933 Feb 2024 → Nov 2025 overdue lung cancer Tongji University Not yet recruiting No outcome recorded
Phase not applicable36 trials · 2 met primary
— NCT07618546 May 2026 → Mar 2027 expected hepatocellular carcinoma Henan Cancer Hospital Not yet recruiting No outcome recorded
— NCT07466901 Apr 2026 → Apr 2030 expected cervical cancer Jin Li Not yet recruiting No outcome recorded
— NCT07491822 Mar 2026 → Sep 2027 expected triple-negative breast carcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
— NCT07067450 Jul 2025 → Dec 2026 expected esophageal squamous cell carcinoma Sichuan University Not yet recruiting No outcome recorded
— NCT06740370 Dec 2024 → Dec 2025 overdue hepatocellular carcinoma Sun Yat-sen University Recruiting No outcome recorded
— NCT06622031 Oct 2024 → Dec 2026 expected hepatocellular carcinoma, portal vein thrombosis Sun Yat-sen University Recruiting No outcome recorded
— NCT06061276 May 2024 → Jun 2025 overdue hepatocellular carcinoma Sun Yat-sen University Recruiting No outcome recorded
— NCT06215677 Jan 2024 → May 2025 overdue colon carcinoma Peking Union Medical College Hospital Recruiting No outcome recorded
— NCT05772273 Mar 2023 → Jul 2027 expected acute myeloid leukemia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
— NCT05715632 Feb 2023 → Mar 2024 gastric cancer Tang-Du Hospital Unknown No outcome recorded
Comparator or background therapy58 trials
Phase 1 NCT06896422 Background Jun 2025 → Dec 2026 expected non-small cell lung carcinoma The First Affiliated Hospital of Zhengzhou University Recruiting No outcome recorded
Phase 1 NCT06121557 Background Nov 2023 → Dec 2026 expected breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 1 NCT05429398 Background Jun 2022 → Aug 2023 neoplasm Shanghai YingLi Pharmaceutical Co. Ltd. Unknown No outcome recorded
Phase 1/2 NCT04929652 Background Jun 2021 → Jun 2022 colorectal cancer Jiangsu Cancer Institute & Hospital Unknown No outcome recorded
Phase 2 NCT07824856 Background Oct 2026 → Aug 2028 expected metastatic neoplasm, nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2026-01-05 Hutchison Medipharma Limited HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma hutch-med.com ↗
2024-05-14 Hutchison Medipharma Limited HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui hutch-med.com ↗
2015-09-02 Incyte Corporation Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody incyte.com ↗

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 587 sources stand behind the page.

FieldValueCited text
Known as camrelizumab “This study evaluated the efficacy and safety of a novel, fully China-developed combination therapy-comprising inetetamab (an anti-HER2 monoclonal antibody), camrelizumab (an...” PMID 41593669 ↗ Jan 2026
491

“a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until...” NCT06675214 ↗

“Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer...” NCT03813784 ↗

“Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab...” NCT06259721 ↗

“Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the...” NCT05048017 ↗

“Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or...” NCT06086457 ↗

“Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2,...” NCT05182944 ↗

“The aim of this study is to evaluate the clinical efficacy and safety of D-BACE combined with neoadjuvant chemotherapy and camrelizumab in patients with resectable stage...” NCT07016126 ↗

“We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating agent, decitabine, improves progression-free survival (PFS) in patients with...” PMID 33820822 ↗ Apr 2021

“Camrelizumab, a PD-1 inhibitor produced by Hengrui, has been approved for the treatment of various malignant tumors including advanced lung cancer, advanced liver cancer and...” NCT05475678 ↗

“Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗

Show 481 more sources
Known as Aikening “PD-1 inhibitor (Camrelizumab for injection, Aikening): 200 mg per dose, infused over 30 to 60 minutes.” NCT06866951 ↗
Known as AiRuiKa “Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the...” NCT05048017 ↗
1

“Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the...” NCT05438706 ↗
Known as CAM “neoadjuvant short-course radiotherapy (SCRT) followed by camrelizumab (CAM) and CAPOX” PMID 42292847 ↗ May 2026
Known as Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China) “Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China)” NCT05742750 ↗
1

“Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China)” NCT04642664 ↗
Known as Camrelizumab for injection “Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks” NCT04510064 ↗
3

“Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets” NCT05313282 ↗

“Camrelizumab for injection” NCT05809336 ↗

“Camrelizumab for Injection” NCT04812002 ↗
Known as Carilizumab “Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma” NCT04588987 ↗
3

NCT07236528 ↗

NCT06792162 ↗

NCT04537286 ↗
Known as Carrelizumab “Carrelizumab is a human high-affinity IgG4 anti-PD-1 monoclonal antibody drug independently developed by Suzhou Henrui Pharmaceutical Co., Ltd., which can selectively block the...” NCT04909866 ↗
12

“This study is to analyze the safety and efficacy of drug-eluting beads transarterial chemoembolization combined with apatinib and carrelizumab injection in the treatment of ICC...” NCT04834674 ↗

“Carrelizumab: 200mg, ivgtt, d1, q3w Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil...” NCT05610332 ↗

“This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis” NCT04523662 ↗

“Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.” NCT04997837 ↗

“Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.” NCT05737563 ↗

“Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle.” NCT06199882 ↗

NCT05576272 ↗

NCT05715632 ↗

NCT05697237 ↗

NCT04997850 ↗

Show 2 more sources
Known as SHR-1210 “Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer...” NCT03813784 ↗
105

“The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally...” NCT04221516 ↗

“Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II...” NCT04126993 ↗

“Clinical Study of PD-1 Monoclonal Antibody SHR-1210 Combined With Epirubicin in the Treatment of Extensive Small Cell Lung Cancer After First-line Treatment Failure” NCT03755115 ↗

“Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma” NCT04609176 ↗

“Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210” NCT06276933 ↗

“Drug：Anti-PD-1 antibody Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks. Other names：SHR-1210, Camrelizumab” NCT04665362 ↗

“PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)” NCT06731140 ↗

“PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)” NCT05076682 ↗

“Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg.” NCT04706598 ↗

“PD1 inhibitor Camrelizumab(SHR-1210) combined with DNA methyltransferase inhibitor decitabine” NCT04353479 ↗

Show 95 more sources
Action Inhibit “Camrelizumab inhibits PD-1 in non-clinical models” PMID 32256049 ↗ Mar 2020
Modality Monoclonal antibody “A fully human monoclonal immunoglobulin (IgG4 subtype)” NCT02721589 ↗
Route Intravenous “camrelizumab was administered intravenously at 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks” PMID 32256049 ↗ Mar 2020
Target PDCD1 “PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.” NCT03311789 ↗